Vanda Pharmaceuticals (VNDA) Competitors $4.86 +0.05 (+1.04%) Closing price 04:00 PM EasternExtended Trading$4.76 -0.11 (-2.16%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VNDA vs. NVAX, OPK, GERN, RGLS, ZBIO, MYGN, LXRX, EBS, RIGL, and XOMAShould you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), Zenas BioPharma (ZBIO), Myriad Genetics (MYGN), Lexicon Pharmaceuticals (LXRX), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), and XOMA Royalty (XOMA). These companies are all part of the "biotechnology" industry. Vanda Pharmaceuticals vs. Its Competitors Novavax OPKO Health Geron Regulus Therapeutics Zenas BioPharma Myriad Genetics Lexicon Pharmaceuticals Emergent Biosolutions Rigel Pharmaceuticals XOMA Royalty Vanda Pharmaceuticals (NASDAQ:VNDA) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings. Does the media prefer VNDA or NVAX? In the previous week, Novavax had 8 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 8 mentions for Novavax and 0 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.94 beat Novavax's score of 0.87 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Vanda Pharmaceuticals Positive Novavax Positive Do insiders & institutionals believe in VNDA or NVAX? 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 10.0% of Vanda Pharmaceuticals shares are owned by company insiders. Comparatively, 1.0% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is VNDA or NVAX more profitable? Novavax has a net margin of 38.14% compared to Vanda Pharmaceuticals' net margin of -21.98%. Vanda Pharmaceuticals' return on equity of -8.30% beat Novavax's return on equity.Company Net Margins Return on Equity Return on Assets Vanda Pharmaceuticals-21.98% -8.30% -6.85% Novavax 38.14%-115.51%29.99% Do analysts prefer VNDA or NVAX? Vanda Pharmaceuticals presently has a consensus price target of $16.50, indicating a potential upside of 239.51%. Novavax has a consensus price target of $17.00, indicating a potential upside of 142.86%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Novavax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vanda Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Novavax 2 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.29 Which has more volatility & risk, VNDA or NVAX? Vanda Pharmaceuticals has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Novavax has a beta of 2.69, meaning that its share price is 169% more volatile than the S&P 500. Which has higher valuation and earnings, VNDA or NVAX? Vanda Pharmaceuticals has higher earnings, but lower revenue than Novavax. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVanda Pharmaceuticals$198.77M1.44-$18.90M-$0.75-6.48Novavax$682.16M1.66-$187.50M$2.652.64 SummaryNovavax beats Vanda Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VNDA vs. The Competition Export to ExcelMetricVanda PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$283.48M$2.94B$5.57B$9.35BDividend YieldN/A2.45%3.80%4.06%P/E Ratio-6.4820.1528.0719.86Price / Sales1.44302.32441.4199.96Price / CashN/A43.1635.8457.94Price / Book0.537.838.265.67Net Income-$18.90M-$55.11M$3.24B$257.80M7 Day Performance-2.61%2.18%0.51%1.07%1 Month Performance8.24%12.98%7.99%11.31%1 Year Performance-21.86%1.98%28.68%17.01% Vanda Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VNDAVanda Pharmaceuticals4.7021 of 5 stars$4.86+1.0%$16.50+239.5%-22.8%$283.48M$198.77M-6.48290NVAXNovavax4.3551 of 5 stars$6.97+1.9%$17.00+143.9%-57.7%$1.13B$1.21B2.631,990OPKOPKO Health4.1075 of 5 stars$1.34-0.7%$2.75+105.2%-5.6%$1.06B$713.10M-19.142,997Positive NewsGERNGeron3.4578 of 5 stars$1.34+1.5%$4.61+244.1%-74.5%$853.47M$116.29M-6.3870RGLSRegulus Therapeutics1.6667 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830ZBIOZenas BioPharma1.5836 of 5 stars$12.82+14.7%$36.67+186.0%N/A$536.26M$5M-3.61N/APositive NewsMYGNMyriad Genetics4.5918 of 5 stars$5.22-2.2%$14.38+175.6%-81.5%$481.16M$831.30M-4.662,700Positive NewsLXRXLexicon Pharmaceuticals2.5603 of 5 stars$1.18+9.3%$3.67+210.7%-42.2%$426.56M$31.21M-2.31140EBSEmergent Biosolutions4.1581 of 5 stars$7.28-1.1%$14.33+96.9%-42.3%$395.09M$930.30M-2.692,420RIGLRigel Pharmaceuticals3.1104 of 5 stars$19.35+2.5%$36.40+88.1%+71.4%$345.78M$179.28M9.35160Positive NewsXOMAXOMA Royalty3.8116 of 5 stars$27.76+2.3%$69.50+150.4%-1.4%$332.20M$13.05M-24.1410 Related Companies and Tools Related Companies Novavax Competitors OPKO Health Competitors Geron Competitors Regulus Therapeutics Competitors Zenas BioPharma Competitors Myriad Genetics Competitors Lexicon Pharmaceuticals Competitors Emergent Biosolutions Competitors Rigel Pharmaceuticals Competitors XOMA Royalty Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VNDA) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
